Why the study?
Therapy with angiogenesis inhibitors is effective in cancer treatment but carries a risk of cardiotoxicity, demanding an interdisciplinary understanding of its molecular mechanisms.
What are the molecular mechanisms and risk factors for cardiotoxicity associated with antiangiogenic drugs?
What are the molecular mechanisms and risk factors for cardiotoxicity associated with antiangiogenic drugs?
Antiangiogenic drugs carry a significant risk of cardiotoxicity, including heart failure and hypertension, highlighting the need for interdisciplinary cardio-oncology management.
Answers are grounded in this paper and cite their sources.
May warrant cardiac surveillance in antiangiogenic therapy; leaves open optimal risk stratification and mitigation strategies.
Therapy with angiogenesis inhibitors is undoubtedly an advancement in cancer treatment; however, it is associated with a risk of developing cardiotoxicity, which most often manifests in myocardial contractile dysfunction or an increased risk of thromboembolic events. Heart failure is observed in 2–4% of patients treated with bevacizumab and in 3–8% of patients on antiangiogenic tyrosine kinase inhibitors. The proposed pathomechanisms underlying the impairment in systolic function during antiangiogenic drug treatment include mitochondrial dysfunction, a secondary reduction in cardiomyocyte ATP production and redox imbalance, which may contribute to pathological states known as “free radical diseases”. Additionally, therapy with angiogenesis inhibitors may also cause cardiac oxidative stress. The risk factors for cardiac complications include arterial hypertension, which is a known “class effect” of this class of drugs, as well as a number of other factors such as age, comorbidities, prior radiotherapy and baseline left ventricular ejection fraction. The cardiovascular diseases are still the first cause of death in the world. The more effective oncological treatment becomes, the more often comorbidities occur. This fact seems to demand interdisciplinary approach from investigators and practitioners. This article presents the current state of knowledge on the molecular mechanisms of cardiotoxicity of antiangiogenic drugs used in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Tomaszewska et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: